Rubedo Life Sciences tackles inflammatory skin disease with small molecule therapy that targets senescent cells that drive cellular aging.
Biopharmaceutical company Rubedo Life Sciences has presented its in vivo efficacy data for its small molecule therapy targeting senescent cells that drive cellular aging to treat dermatological diseases. The data was presented during the 2023 American Academy of Dermatology (AAD) conference week, a gathering of the largest, most influential, and representative dermatology group, with a membership of more than 20,500 physicians worldwide.
Longevity.Technology: Rubedo is committed to developing first-in-class disease-modifying therapies for chronic age-related diseases, and to that end is developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Its proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders.
Speaking at the conference, Rubedo announced that histopathological assessment showed that the company’s lead compound significantly reduced senescence signatures associated with skin senescent cells, and significantly improved skin pathophysiological manifestations, such as chronic desquamation in preclinical animal models of chemotherapy-induced skin fibrosis and dermatitis.
“We’re excited to present for the first time, efficacy data of our lead compound that compares favorably to standard of care and supports further development,” said Ofir Moreno, PhD, Senior Vice President, Drug Discovery at Rubedo, who presented the data at the Oncodermatology Society conference.
“By targeting the pathologic cells that drive aging, our approach has demonstrated a robust response targeting a fundamental mechanism which leads to inflammatory dermatological diseases such as chronic atopic dermatitis, plaque psoriasis, and chemotherapy-induced skin fibrosis and alopecia which are common side-effects of cancer treatment, and drivers of an accelerated biological aging process [1].”
“We’re thrilled to present this data to key opinion leaders in the longevity field, ahead of our nomination of a clinical candidate for our dermatology program targeting skin senescent cell types that drive chronic degenerative dermatological conditions associated with biological aging processes,” said Marco Quarta, PhD, CEO & Founder, Rubedo Life Sciences [1].
Rubedo is planning first-in-human studies in multiple skin indications driven by chronic inflammation and degenerative fibrosis. Leveraging its proprietary single-cell multiomics platform ALEMBIC™, Rubedo identifies pathologic cells with senescence features characteristic of multiple dermatological chronic skin conditions, and is developing potent and selective compounds targeting those cells using its selective senolytic platform SenTech™.
